Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL31113175 | 0.98 | JAK2 (0.37) | JAK2MAP4K4KDM4EALDH1A1GLA | |
| SCHEMBL419049 | 0.75 | KDM4E (0.36) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL2508471 | 0.75 | KDM4E (0.36) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL5634584 | 0.72 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL30886385 | 0.71 | MAP4K4 (0.44) | MAP4K4KDM4EALDH1A1HPGDMAPK8 | |
| SCHEMBL24198347 | 0.71 | MAP4K4 (0.35) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL4225125 | 0.71 | DYRK1A (0.37) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL519222 | 0.71 | TGFBR1 (0.34) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL5992410 | 0.71 | ALDH1A1 (0.33) | MAP4K4KDM4EALDH1A1GLAGAA | |
| SCHEMBL18237629 | 0.71 | MAPT (0.34) | MAP4K4KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | claimed |
| CN-120025352-A | Condensed heterocyclic compound, pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-116478171-A | Simple preparation method of 4-amino-7-halogenopyrrolo [2, l-f ] [ l,2,4] triazine | 威海同丰海洋生物科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250388561-A1 | A BICYCLOPENTYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-12-25 | — | — | US | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4225282-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | ATEA Pharmaceuticals, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116478171-A | Simple preparation method of 4-amino-7-halogenopyrrolo [2, l-f ] [ l,2,4] triazine | 威海同丰海洋生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022076903-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-104788460-A | Preparation method of 4-aromatic amino pyrrolo-[2, 1-f][1, 2, 4] triazine derivative | UNIV SHAANXI NORMAL | 2015-07-22 | — | — | CN | disclosed |
| CN-104788460-A | Preparation method of 4-aromatic amino pyrrolo-[2, 1-f][1, 2, 4] triazine derivative | UNIV SHAANXI NORMAL | 2015-07-22 | — | — | CN | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | JAK2 4585/4885MAP4K4 3297/4885KDM4E 2994/4885 |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | JAK2 143/4885MAP4K4 92/4885KDM4E 1400/4885 |
| US-20250388561-A1 | A BICYCLOPENTYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | BACE1, BACE2, CYP3A43 | JAK2 4220/4885MAP4K4 4389/4885KDM4E 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.